Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Research output: Contribution to journalLetterResearchpeer-review

  5. Yet another susceptibility variant for ALL: what's next?

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Increased risk of anemia, neutropenia and thrombocytopenia in people with HIV and well-controlled viral replication

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Blodsygdomme

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

  • Emanuele Zucca
  • Stephanie Rondeau
  • Anna Vanazzi
  • Bjorn Østenstad
  • Ulrich J M Mey
  • Daniel Rauch
  • Björn E Wahlin
  • Felicitas Hitz
  • Micaela Hernberg
  • Ann-Sofie Johansson
  • Peter de Nully Brown
  • Hans Hagberg
  • Andrés J M Ferreri
  • Andreas Lohri
  • Urban Novak
  • Thilo Zander
  • Hanne Bersvendsen
  • Mario Bargetzi
  • Walter Mingrone
  • Fatime Krasniqi
  • Stefan Dirnhofer
  • Stefanie Hayoz
  • Hanne Hawle
  • Simona Berardi Vilei
  • Michele Ghielmini
  • Eva Kimby
View graph of relations

The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m 2 IV on day 1 of weeks 1-4 and repeated during weeks 12-15 in responding patients) or rituximab (same schedule) in combination with lenalidomide (15 mg orally daily for 18 weeks). Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 months. In total, 77 patients were allocated to rituximab monotherapy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score in each arm). A significantly higher CR/CRu rate at 6 months was documented in the combination arm by the investigators (36%; 95% confidence interval [CI], 26%-48% vs 25%; 95% CI, 16%-36%) and confirmed by an independent response review of computed tomography scans only (61%; 95% CI, 49%-72% vs 36%; 95% CI, 26%-48%). After a median follow-up of 4 years, significantly higher 30-month CR/CRu rates and longer progression-free survival (PFS) and time to next treatment (TTNT) were observed for the combination. Overall survival (OS) rates were similar in both arms (‡90%). Toxicity grade ‡3 was more common in the combination arm (56% vs 22% of patients), mainly represented by neutropenia (23% vs 7%). Addition of lenalidomide to rituximab significantly improved CR/CRu rates, PFS, and TTNT, with expected higher, but manageable toxicity. The excellent OS in both arms suggests that chemotherapy-free strategies should be further explored. This trial was registered at as #NCT01307605.

Original languageEnglish
Issue number4
Pages (from-to)353-362
Number of pages10
Publication statusPublished - 2019

Bibliographical note

© 2019 by The American Society of Hematology.

ID: 57439528